Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: kerwin l. Med. 2024 Jan 12;5(1):42-61.e23. doi: 10.1016/j.medj.2023.12.004. Epub 2024 Jan 4. Med. 2024. PMID: 38181791 Free article.
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Duty JA, et al. Among authors: kerwin l. Med. 2022 Oct 14;3(10):705-721.e11. doi: 10.1016/j.medj.2022.08.002. Epub 2022 Aug 8. Med. 2022. PMID: 36044897 Free PMC article.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, Sattler RA, Manning JT, Singh A, Lim R, Healy LD, Johnson S, Paz Cabral E, Li D, Lu L, Ledesma A, Lee D, Richards S, Rivero-Nava L, Li Y, Shen W, Stegman K, Blair B, Urata S, Kishimoto-Urata M, Ko J, Du N, Morais K, Lawrence K, Rivera I, Pai CI, Bresson D, Brunswick M, Zhang Y, Ji H, Paessler S, Allen RD. Cao X, et al. Among authors: kerwin l. Sci Rep. 2022 Sep 15;12(1):15517. doi: 10.1038/s41598-022-19780-7. Sci Rep. 2022. PMID: 36109550 Free PMC article.
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
Wang YT, Allen RD 3rd, Kim K, Shafee N, Gonzalez AJ, Nguyen MN, Valentine KM, Cao X, Lu L, Pai CI, Johnson S, Kerwin L, Zhou H, Zhang Y, Shresta S. Wang YT, et al. Among authors: kerwin l. Antiviral Res. 2021 Nov;195:105185. doi: 10.1016/j.antiviral.2021.105185. Epub 2021 Oct 8. Antiviral Res. 2021. PMID: 34634289 Free PMC article.
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
Lim RK, Buschman M, Khasanov A, Ledesma A, Chen J, Nguyen T, Guo J, Li L, Huang J, Niu J, Kerwin L, Wang R, Guo Y, Zhu T, Kaufmann G, Zhang Y, Zhou H, Ji H, Fu Y. Lim RK, et al. Among authors: kerwin l. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1137-1149. doi: 10.1080/14712598.2023.2292633. Epub 2023 Dec 15. Expert Opin Biol Ther. 2023. PMID: 38078403
PSMA-targeted bispecific Fab conjugates that engage T cells.
Patterson JT, Isaacson J, Kerwin L, Atassi G, Duggal R, Bresson D, Zhu T, Zhou H, Fu Y, Kaufmann GF. Patterson JT, et al. Among authors: kerwin l. Bioorg Med Chem Lett. 2017 Dec 15;27(24):5490-5495. doi: 10.1016/j.bmcl.2017.09.065. Epub 2017 Oct 6. Bioorg Med Chem Lett. 2017. PMID: 29126850
Chemically generated IgG2 bispecific antibodies through disulfide bridging.
Patterson JT, Gros E, Zhou H, Atassi G, Kerwin L, Carmody L, Zhu T, Jones B, Fu Y, Kaufmann GF. Patterson JT, et al. Among authors: kerwin l. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3647-3652. doi: 10.1016/j.bmcl.2017.07.021. Epub 2017 Jul 8. Bioorg Med Chem Lett. 2017. PMID: 28720505
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: kerwin l. Med. 2024 Feb 9;5(2):169-171. doi: 10.1016/j.medj.2024.01.013. Med. 2024. PMID: 38340710 Free article. No abstract available.
Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA, Crannage EF, Kerwin LC, Guyton JE. Coon SA, et al. Among authors: kerwin lc. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1061-1072. doi: 10.1080/17512433.2018.1534201. Epub 2018 Oct 16. Expert Rev Clin Pharmacol. 2018. PMID: 30296182 Review.
55 results